title: Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients.
authors: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
authors: Fabienne
authors: F
authors: McClanahan
authors: John G
authors: JG
authors: Gribben
mesh_terms: D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000628:therapy*